Hematopoietic Recovery and Safety Following Early Romiplostim Administration After Pediatric HSCT: A Prospective Randomized Pilot Study
Pediatric Blood & Cancer · 2026
DOI: 10.1002/1545-5017.70586 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Sanjana Sarangarajan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Oncology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Thrombopoietin, Recombinant Fusion Proteins, Hematopoietic Stem Cell Transplantation, Receptors, Fc. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
Delayed platelet recovery remains a frequent and clinically significant complication following hematopoietic stem cell transplantation (HSCT) in children, contributing to increased transfusion burden, bleeding risk, and prolonged hospitalization. Thrombopoietin receptor agonists (TPO‐RAs), including romiplostim, have demonstrated activity in post‐transplant thrombocytopenia; however, prospective pediatric data on their early post‐transplant use are limited. We evaluated the safety and potential effects of early romiplostim administration on platelet and hematopoietic recovery following pediatric HSCT.
Methods
In this prospective, open‐label, randomized pilot study conducted at a tertiary care center in India, children aged 1–18 years undergoing autologous or allogeneic HSCT were randomized (1:1) to receive standard post‐transplant care with or without romiplostim. Romiplostim (5 µg/kg subcutaneously) was administered on Days +1 and +8 post‐transplant (or Days +5 and +12 for haploidentical transplants with post‐transplant cyclophosphamide). The primary endpoint was time to platelet engraftment (platelet count ≥20 × 10 9 /L for 3 consecutive days without transfusion). Secondary endpoints included platelet transfusion requirements, platelet nadir, platelet counts on Day +28, time to platelet count ≥50 × 10 9 /L, neutrophil recovery, bleeding, and thrombotic events.
Results
Thirty‐two children were enrolled (romiplostim n = 17; control n = 15). Median time to platelet engraftment was comparable between the romiplostim and control groups (12 vs. 12.5 days; p = 0.88), with no significant difference on Kaplan–Meier analysis. Platelet transfusion requirements, platelet nadir, and time to platelet count ≥50 × 10 9 /L were also similar between groups. By Day +28, higher platelet counts were observed in the romiplostim arm, with exploratory subgroup analysis demonstrating higher platelet counts following allogeneic HSCT. Romiplostim recipients also demonstrated higher absolute neutrophil counts on Day +28. No thrombotic events, severe bleeding episodes, or drug‐related serious adverse events were observed.
Conclusion
Early administration of romiplostim following pediatric HSCT was safe and well tolerated, with no significant treatment‐related toxicity observed. Although it did not shorten time to platelet engraftment, exploratory analyses demonstrated higher Day +28 platelet and neutrophil counts, generating the hypothesis that romiplostim may support sustained hematopoietic recovery. These findings require confirmation in larger, adequately powered multicenter studies before conclusions regarding efficacy can be drawn.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Oncology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
- Division of Medical Genetics, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
- Division of Pediatric Neurology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
- Department of Radiodiagnosis and Intervention Radiology, All India Institute of Medical Sciences, New Delhi, India.
- Department of Medical Oncology, Dr BRA, IRCH, All India Institute of Medical Sciences, New Delhi, India.
- Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi, India.
ORCID-Profile: Aditya Kumar Gupta, Biswaroop Chakrabarthy, Sujata Mohanty, Rachna Seth
Zitieren
APA
Sarangarajan, S., Gupta, A. K., Meena, J. P., Gupta, N., Jauhari, P., Chakrabarthy, B., Naranje, P., Pushpam, D., Coshic, P., Mohanty, S., Bakhshi, S., Gulati, S., & Seth, R. (2026). Hematopoietic Recovery and Safety Following Early Romiplostim Administration After Pediatric HSCT: A Prospective Randomized Pilot Study. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70586
Vancouver
Sarangarajan S, Gupta AK, Meena JP, Gupta N, Jauhari P, Chakrabarthy B, et al. Hematopoietic Recovery and Safety Following Early Romiplostim Administration After Pediatric HSCT: A Prospective Randomized Pilot Study. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70586
BibTeX
@article{Sarangarajan2026,
author = {Sarangarajan, Sanjana and Gupta, Aditya Kumar and Meena, Jagdish Prasad and Gupta, Neerja and Jauhari, Prashant and Chakrabarthy, Biswaroop and Naranje, Priyanka and Pushpam, Deepam and Coshic, Poonam and Mohanty, Sujata and Bakhshi, Sameer and Gulati, Sheffali and Seth, Rachna},
title = {Hematopoietic Recovery and Safety Following Early Romiplostim Administration After Pediatric HSCT: A Prospective Randomized Pilot Study},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70586}
}
EUVIMED